1. Home
  2. STHO vs KYTX Comparison

STHO vs KYTX Comparison

Compare STHO & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STHO
  • KYTX
  • Stock Information
  • Founded
  • STHO N/A
  • KYTX 2018
  • Country
  • STHO United States
  • KYTX United States
  • Employees
  • STHO N/A
  • KYTX N/A
  • Industry
  • STHO Real Estate
  • KYTX
  • Sector
  • STHO Real Estate
  • KYTX
  • Exchange
  • STHO Nasdaq
  • KYTX NYSE
  • Market Cap
  • STHO 89.7M
  • KYTX 92.1M
  • IPO Year
  • STHO N/A
  • KYTX 2024
  • Fundamental
  • Price
  • STHO $6.53
  • KYTX $2.11
  • Analyst Decision
  • STHO
  • KYTX Buy
  • Analyst Count
  • STHO 0
  • KYTX 5
  • Target Price
  • STHO N/A
  • KYTX $18.80
  • AVG Volume (30 Days)
  • STHO 93.2K
  • KYTX 203.0K
  • Earning Date
  • STHO 05-20-2025
  • KYTX 05-16-2025
  • Dividend Yield
  • STHO N/A
  • KYTX N/A
  • EPS Growth
  • STHO N/A
  • KYTX N/A
  • EPS
  • STHO N/A
  • KYTX N/A
  • Revenue
  • STHO $113,297,000.00
  • KYTX N/A
  • Revenue This Year
  • STHO N/A
  • KYTX N/A
  • Revenue Next Year
  • STHO N/A
  • KYTX N/A
  • P/E Ratio
  • STHO N/A
  • KYTX N/A
  • Revenue Growth
  • STHO N/A
  • KYTX N/A
  • 52 Week Low
  • STHO $6.09
  • KYTX $1.78
  • 52 Week High
  • STHO $14.50
  • KYTX $17.55
  • Technical
  • Relative Strength Index (RSI)
  • STHO 42.45
  • KYTX 48.82
  • Support Level
  • STHO $6.11
  • KYTX $1.92
  • Resistance Level
  • STHO $7.02
  • KYTX $2.38
  • Average True Range (ATR)
  • STHO 0.35
  • KYTX 0.17
  • MACD
  • STHO 0.06
  • KYTX 0.02
  • Stochastic Oscillator
  • STHO 46.41
  • KYTX 41.30

About STHO Star Holdings Shares of Beneficial Interest

Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.

About KYTX KYVERNA THERAPEUTICS INC

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Share on Social Networks: